메뉴 건너뛰기




Volumn 5, Issue 3, 2010, Pages 287-296

Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy

Author keywords

Allergic conjunctivitis; Antihistamines; Mast cell stabilizers; Ocular allergy; Olopatadine

Indexed keywords

ANTAZOLINE; ARTIFICIAL TEAR; AZELASTINE; BETOTASTINE; CLEMASTINE; CROMOGLYCATE DISODIUM; DESLORATADINE; EMEDASTINE; EPINASTINE; FLUOROMETHOLONE ACETATE; FLUTICASONE FUROATE; HISTAMINE; HISTAMINE H1 RECEPTOR; KETOROLAC; KETOTIFEN; LEUKOTRIENE; LEVOCABASTINE; LOTEPREDNOL ETABONATE; NEDOCROMIL; OLOPATADINE; PEMIROLAST; PHENIRAMINE; PLACEBO; THROMBOXANE;

EID: 77953178590     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.10.28     Document Type: Review
Times cited : (5)

References (68)
  • 1
    • 4544365651 scopus 로고    scopus 로고
    • Ocular allergic disease: Mechanisms, disease sub-types, treatment
    • Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocul. Surf. 1(3), 127-149 (2003).
    • (2003) Ocul. Surf. , vol.1 , Issue.3 , pp. 127-149
    • Abelson, M.B.1    Smith, L.2    Chapin, M.3
  • 2
    • 18844437888 scopus 로고    scopus 로고
    • Allergic rhinoconjunctivitis: Epidemiology
    • Phipatanakul W. Allergic rhinoconjunctivitis: epidemiology. Immunol. Allergy Clin. North Am. 25(2), 263-281 (2005).
    • (2005) Immunol. Allergy Clin. North Am. , vol.25 , Issue.2 , pp. 263-281
    • Phipatanakul, W.1
  • 3
    • 14744306532 scopus 로고    scopus 로고
    • A review of the use of olopatadine in allergic conjunctivitis
    • McGill JI. A review of the use of olopatadine in allergic conjunctivitis. Int. Ophthalmol. 25(3), 171-179 (2004).
    • (2004) Int. Ophthalmol. , vol.25 , Issue.3 , pp. 171-179
    • McGill, J.I.1
  • 5
    • 0033774349 scopus 로고    scopus 로고
    • Conjunctival cytokines in ocular allergy
    • McGill J. Conjunctival cytokines in ocular allergy. Clin. Exp. Allergy 30(10), 1355-1357 (2000).
    • (2000) Clin. Exp. Allergy , vol.30 , Issue.10 , pp. 1355-1357
    • McGill, J.1
  • 7
    • 11344288457 scopus 로고    scopus 로고
    • Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment
    • Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol. 115(1), 118-122 (2005).
    • (2005) J. Allergy Clin. Immunol. , vol.115 , Issue.1 , pp. 118-122
    • Ono, S.J.1    Abelson, M.B.2
  • 8
    • 0033694389 scopus 로고    scopus 로고
    • Tear and conjunctival changes during the allergen-induced early- and late-phase responses
    • Bacon AS, Ahluwalia P, Irani AM et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J. Allergy Clin. Immunol. 106(5), 948-954 (2000).
    • (2000) J. Allergy Clin. Immunol. , vol.106 , Issue.5 , pp. 948-954
    • Bacon, A.S.1    Ahluwalia, P.2    Irani, A.M.3
  • 10
    • 33745673180 scopus 로고    scopus 로고
    • Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures
    • Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin. Exp. Allergy 36(6), 777-784 (2006).
    • (2006) Clin. Exp. Allergy , vol.36 , Issue.6 , pp. 777-784
    • Leonardi, A.1    Curnow, S.J.2    Zhan, H.3    Calder, V.L.4
  • 11
    • 0030816459 scopus 로고    scopus 로고
    • Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration
    • Anderson DF, MacLeod JD, Baddeley SM et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration. Clin. Exp. Allergy 27(9), 1060-1066 (1997).
    • (1997) Clin. Exp. Allergy , vol.27 , Issue.9 , pp. 1060-1066
    • Anderson, D.F.1    MacLeod, J.D.2    Baddeley, S.M.3
  • 12
    • 0025284670 scopus 로고
    • Human conjunctival mast cells: Distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis
    • Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy Clin. Immunol. 86(1), 34-40 (1990).
    • (1990) J. Allergy Clin. Immunol. , vol.86 , Issue.1 , pp. 34-40
    • Irani, A.M.1    Butrus, S.I.2    Tabbara, K.F.3    Schwartz, L.B.4
  • 13
  • 16
    • 0031917407 scopus 로고    scopus 로고
    • Isolation of human conjunctival mast cells and epithelial cells: Tumor necrosis factor-A from mast cells affects intercellular adhesion molecule 1 expression on epithelial cells
    • Cook EB, Stahl JL, Miller ST et al. Isolation of human conjunctival mast cells and epithelial cells: tumor necrosis factor-a from mast cells affects intercellular adhesion molecule 1 expression on epithelial cells. Invest. Ophthalmol. Vis. Sci. 39(2), 336-343 (1998).
    • (1998) Invest. Ophthalmol. Vis. Sci. , vol.39 , Issue.2 , pp. 336-343
    • Cook, E.B.1    Stahl, J.L.2    Miller, S.T.3
  • 17
    • 0035985268 scopus 로고    scopus 로고
    • Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug
    • Ohmori K, Hayashi K, Kaise T et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J. Pharmacol. 88(4), 379-397 (2002).
    • (2002) Jpn J. Pharmacol. , vol.88 , Issue.4 , pp. 379-397
    • Ohmori, K.1    Hayashi, K.2    Kaise, T.3
  • 18
    • 4544333095 scopus 로고    scopus 로고
    • A review of olopatadine for the treatment of ocular allergy
    • Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin. Pharmacother. 5(9), 1979-1994 (2004).
    • (2004) Expert Opin. Pharmacother. , vol.5 , Issue.9 , pp. 1979-1994
    • Abelson, M.B.1
  • 19
    • 10644237902 scopus 로고    scopus 로고
    • Properties of olopatadine hydrochloride, a new antiallergic/ antihistaminic drug
    • Ohmori K, Hasegawa K, Tamura T et al. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung 54(12), 809-829 (2004).
    • (2004) Arzneimittelforschung , vol.54 , Issue.12 , pp. 809-829
    • Ohmori, K.1    Hasegawa, K.2    Tamura, T.3
  • 20
    • 0029853560 scopus 로고    scopus 로고
    • Olopatadine (AL-4943A): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis
    • Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 12(4), 401-407 (1996).
    • (1996) J. Ocul. Pharmacol. Ther. , vol.12 , Issue.4 , pp. 401-407
    • Sharif, N.A.1    Xu, S.X.2    Yanni, J.M.3
  • 21
    • 0030427026 scopus 로고    scopus 로고
    • Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases
    • Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J. Pharmacol. Exp. Ther. 278(3), 1252-1261 (1996).
    • (1996) J. Pharmacol. Exp. Ther. , vol.278 , Issue.3 , pp. 1252-1261
    • Sharif, N.A.1    Xu, S.X.2    Miller, S.T.3    Gamache, D.A.4    Yanni, J.M.5
  • 23
    • 0029960602 scopus 로고    scopus 로고
    • The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent
    • Yanni JM, Stephens DJ, Miller ST et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J. Ocul. Pharmacol. Ther. 12(4), 389-400 (1996).
    • (1996) J. Ocul. Pharmacol. Ther. , vol.12 , Issue.4 , pp. 389-400
    • Yanni, J.M.1    Stephens, D.J.2    Miller, S.T.3
  • 24
  • 26
    • 0035170468 scopus 로고    scopus 로고
    • Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells
    • Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann. Allergy Asthma Immunol. 87(5), 424-429 (2001).
    • (2001) Ann. Allergy Asthma Immunol. , vol.87 , Issue.5 , pp. 424-429
    • Cook, E.B.1    Stahl, J.L.2    Barney, N.P.3    Graziano, F.M.4
  • 28
    • 0036893417 scopus 로고    scopus 로고
    • Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities
    • Kajita J, Inano K, Fuse E, Kuwabara T, Kobayashi H. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab. Dispos. 30(12), 1504-1511 (2002).
    • (2002) Drug Metab. Dispos. , vol.30 , Issue.12 , pp. 1504-1511
    • Kajita, J.1    Inano, K.2    Fuse, E.3    Kuwabara, T.4    Kobayashi, H.5
  • 29
    • 0032510552 scopus 로고    scopus 로고
    • Unique binding pocket for KW-4679 in the histamine H1 receptor
    • Nonaka H, Otaki S, Ohshima E et al. Unique binding pocket for KW-4679 in the histamine H1 receptor. Eur. J. Pharmacol. 345(1), 111-117 (1998).
    • (1998) Eur. J. Pharmacol. , vol.345 , Issue.1 , pp. 111-117
    • Nonaka, H.1    Otaki, S.2    Ohshima, E.3
  • 30
    • 0032942496 scopus 로고    scopus 로고
    • Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs
    • Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch. Ophthalmol. 117(5), 643-647 (1999).
    • (1999) Arch. Ophthalmol. , vol.117 , Issue.5 , pp. 643-647
    • Yanni, J.M.1    Weimer, L.K.2    Sharif, N.A.3    Xu, S.X.4    Gamache, D.A.5    Spellman, J.M.6
  • 31
    • 0032586312 scopus 로고    scopus 로고
    • A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: Effects of new topical ocular drugs
    • Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol. Scand. 77(228), 33-37 (1999).
    • (1999) Acta Ophthalmol. Scand. , vol.77 , Issue.228 , pp. 33-37
    • Yanni, J.M.1    Sharif, N.A.2    Gamache, D.A.3    Miller, S.T.4    Weimer, L.K.5    Spellman, J.M.6
  • 32
    • 33645218733 scopus 로고    scopus 로고
    • Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein
    • Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K. Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm. 2006(1), 42726 (2006).
    • (2006) Mediators Inflamm , vol.2006 , Issue.1 , pp. 42726
    • Kishimoto, K.1    Kaneko, S.2    Ohmori, K.3    Tamura, T.4    Hasegawa, K.5
  • 34
    • 33751018555 scopus 로고    scopus 로고
    • Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice
    • Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens 32(6), 272-276 (2006).
    • (2006) Eye Contact Lens , vol.32 , Issue.6 , pp. 272-276
    • Villareal, A.L.1    Farley, W.2    Pflugfelder, S.C.3
  • 35
    • 0025166468 scopus 로고
    • Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis
    • Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch. Ophthalmol. 108(1), 84-88 (1990).
    • (1990) Arch. Ophthalmol. , vol.108 , Issue.1 , pp. 84-88
    • Abelson, M.B.1    Chambers, W.A.2    Smith, L.M.3
  • 36
    • 0032100735 scopus 로고    scopus 로고
    • Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity
    • Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am. J. Ophthalmol. 125(6), 797-804 (1998).
    • (1998) Am. J. Ophthalmol. , vol.125 , Issue.6 , pp. 797-804
    • Abelson, M.B.1    Spitalny, L.2
  • 37
    • 0242677574 scopus 로고    scopus 로고
    • Double-masked, randomized, placebo-controlled controlled clinical study of the mast cell stabilizing effect of treatment with olopatadine in the conjunctival allergen challenge model in humans
    • Leonardi AA, Abelson MB. Double-masked, randomized, placebo-controlled controlled clinical study of the mast cell stabilizing effect of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther. 25(10), 2539-2552 (2003).
    • (2003) Clin. Ther. , vol.25 , Issue.10 , pp. 2539-2552
    • Leonardi, A.A.1    Abelson, M.B.2
  • 38
    • 0042703264 scopus 로고    scopus 로고
    • One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears
    • Abelson MB, Pratt S, Mussoline JF, Townsend D. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears. Clin. Ther. 25(7), 2070-2084 (2003).
    • (2003) Clin. Ther. , vol.25 , Issue.7 , pp. 2070-2084
    • Abelson, M.B.1    Pratt, S.2    Mussoline, J.F.3    Townsend, D.4
  • 39
    • 0032586308 scopus 로고    scopus 로고
    • Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model
    • Deschenes J, Discepola M, Abelson MB. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol. Scand. Suppl. 228, 47-52 (1999).
    • (1999) Acta Ophthalmol. Scand. Suppl. , vol.228 , pp. 47-52
    • Deschenes, J.1    Discepola, M.2    Abelson, M.B.3
  • 40
    • 0034527824 scopus 로고    scopus 로고
    • Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model
    • Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. 22(12), 1462-1472 (2000).
    • (2000) Clin. Ther. , vol.22 , Issue.12 , pp. 1462-1472
    • Butrus, S.1    Greiner, J.V.2    Discepola, M.3    Finegold, I.4
  • 41
    • 0033900965 scopus 로고    scopus 로고
    • A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model
    • Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 22(7), 826-833 (2000).
    • (2000) Clin. Ther. , vol.22 , Issue.7 , pp. 826-833
    • Berdy, G.J.1    Spangler, D.L.2    Bensch, G.3    Berdy, S.S.4    Brusatti, R.C.5
  • 42
    • 4344693341 scopus 로고    scopus 로고
    • Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: A double-masked environmental study of patient preference
    • Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked environmental study of patient preference. Curr. Med. Res. Opin. 20(8), 1167-1173 (2004).
    • (2004) Curr. Med. Res. Opin. , vol.20 , Issue.8 , pp. 1167-1173
    • Leonardi, A.1    Zafirakis, P.2
  • 43
    • 0035986660 scopus 로고    scopus 로고
    • Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model
    • Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin. Ther. 24(6), 918-929 (2002).
    • (2002) Clin. Ther. , vol.24 , Issue.6 , pp. 918-929
    • Berdy, G.J.1    Stoppel, J.O.2    Epstein, A.B.3
  • 44
    • 0034869181 scopus 로고    scopus 로고
    • Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.5% ophthalmic solution in the conjunctival allergen challenge model
    • Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.5% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 23(8), 1272-1280 (2001).
    • (2001) Clin. Ther. , vol.23 , Issue.8 , pp. 1272-1280
    • Spangler, D.L.1    Bensch, G.2    Berdy, G.J.3
  • 45
    • 77953183483 scopus 로고    scopus 로고
    • In vitro analysis of antagonism of the histamine H1 receptor by epinastine: A kinetic comparison with other marketed compounds
    • Presented at: Fort Lauderdale, FL, USA, 30 April-4 May (Abstract 4975)
    • Brubaker K, Wright RC, Yerxa BR, Bayer JL. In vitro analysis of antagonism of the histamine H1 receptor by epinastine: a kinetic comparison with other marketed compounds. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 30 April-4 May 2006 (Abstract 4975).
    • (2006) Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
    • Brubaker, K.1    Wright, R.C.2    Yerxa, B.R.3    Bayer, J.L.4
  • 46
  • 47
    • 33845203842 scopus 로고    scopus 로고
    • Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: A post hoc analysis of data from a conjunctival allergen challenge study
    • Finegold I, Granet DB, D'Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin. Ther. 28(10), 1630-1638 (2006).
    • (2006) Clin. Ther. , vol.28 , Issue.10 , pp. 1630-1638
    • Finegold, I.1    Granet, D.B.2    D'Arienzo, P.A.3    Epstein, A.B.4
  • 48
    • 41649107449 scopus 로고    scopus 로고
    • Evaluation of 0.1% olopatadine hydrochloride ophthalmic solution for allergic conjunctivitis
    • Sumi T, Fukushima A, Sawada K et al. Evaluation of 0.1% olopatadine hydrochloride ophthalmic solution for allergic conjunctivitis. Rinsho Ganka 62, 313-317 (2008).
    • (2008) Rinsho Ganka , vol.62 , pp. 313-317
    • Sumi, T.1    Fukushima, A.2    Sawada, K.3
  • 49
    • 0042672615 scopus 로고    scopus 로고
    • Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis
    • Yaylali V, Demirlenk I, Tatlipinar S et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol. Scand. 81(4), 378-382 (2003).
    • (2003) Acta Ophthalmol. Scand. , vol.81 , Issue.4 , pp. 378-382
    • Yaylali, V.1    Demirlenk, I.2    Tatlipinar, S.3
  • 50
    • 0033626460 scopus 로고    scopus 로고
    • Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate
    • Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol. Scand. Suppl. 230, 52-55 (2000).
    • (2000) Acta Ophthalmol. Scand. Suppl. , vol.230 , pp. 52-55
    • Aguilar, A.J.1
  • 51
    • 27744515086 scopus 로고    scopus 로고
    • Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: A 30-day, randomized, double-masked, artificial tear substitute-controlled trial
    • Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin. Ther. 27(9), 1392-1402 (2005).
    • (2005) Clin. Ther. , vol.27 , Issue.9 , pp. 1392-1402
    • Avunduk, A.M.1    Tekelioglu, Y.2    Turk, A.3    Akyol, N.4
  • 52
    • 70350728830 scopus 로고    scopus 로고
    • Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: A placebo-controlled environmental trial
    • Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol. 87(5), 549-554 (2009).
    • (2009) Acta Ophthalmol , vol.87 , Issue.5 , pp. 549-554
    • Borazan, M.1    Karalezli, A.2    Akova, Y.A.3    Akman, A.4    Kiyici, H.5    Erbek, S.S.6
  • 53
    • 0036672810 scopus 로고    scopus 로고
    • Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: An open-label study
    • Dogru M, Ozmen A, Ertürk H, Sanli O, Karatas A. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study. Clin. Ther. 24(8), 1309-1321 (2002).
    • (2002) Clin. Ther. , vol.24 , Issue.8 , pp. 1309-1321
    • Dogru, M.1    Ozmen, A.2    Ertürk, H.3    Sanli, O.4    Karatas, A.5
  • 54
    • 72149104776 scopus 로고    scopus 로고
    • Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A Phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children
    • Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    • Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a Phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin. Ther. 31(9), 1908-1921 (2009).
    • (2009) Clin. Ther. , vol.31 , Issue.9 , pp. 1908-1921
    • Abelson, M.B.1    Torkildsen, G.L.2    Williams, J.I.3    Gow, J.A.4    Gomes, P.J.5    McNamara, T.R.6
  • 55
    • 77953217041 scopus 로고    scopus 로고
    • Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
    • Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clin. Ophthalmol. 2(3), 525-531 (2008).
    • (2008) Clin. Ophthalmol. , vol.2 , Issue.3 , pp. 525-531
    • Uchio, E.1
  • 56
    • 25444463056 scopus 로고    scopus 로고
    • Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: A review of pre-clinical and clinical research
    • Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr. Med. Res. Opin. 21(9), 1377-1387 (2005).
    • (2005) Curr. Med. Res. Opin. , vol.21 , Issue.9 , pp. 1377-1387
    • Rosenwasser, L.J.1    O'Brien, T.2    Weyne, J.3
  • 57
    • 57349129527 scopus 로고    scopus 로고
    • Comparison of the conjunctival toxicity of topical ocular antiallergic agents
    • Lee JS, Lee JE, Kim N, Oum BS. Comparison of the conjunctival toxicity of topical ocular antiallergic agents. J. Ocul. Pharmacol. Ther. 24(6), 557-562 (2008).
    • (2008) J. Ocul. Pharmacol. Ther. , vol.24 , Issue.6 , pp. 557-562
    • Lee, J.S.1    Lee, J.E.2    Kim, N.3    Oum, B.S.4
  • 58
    • 68949206609 scopus 로고    scopus 로고
    • Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model
    • Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol. 28(9), 5 (2009).
    • (2009) BMC Ophthalmol , vol.28 , Issue.9 , pp. 5
    • Khoh-Reiter, S.1    Jessen, B.A.2
  • 59
    • 69749121407 scopus 로고    scopus 로고
    • Multiple action agents and the eye: Do they really stabilize mast cells?
    • Lambiase A, Micera A, Bonini S. Multiple action agents and the eye: do they really stabilize mast cells? Curr. Opin. Allergy Clin. Immunol. 9(5), 454-465 (2009).
    • (2009) Curr. Opin. Allergy Clin. Immunol. , vol.9 , Issue.5 , pp. 454-465
    • Lambiase, A.1    Micera, A.2    Bonini, S.3
  • 60
    • 44349140637 scopus 로고    scopus 로고
    • Olopatadine 0.2% ophthalmic solution: The first ophthalmic antiallergy agent with once-daily dosing
    • Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin. Drug Metab. Toxicol. 4(4), 453-461 (2008).
    • (2008) Expert Opin. Drug Metab. Toxicol. , vol.4 , Issue.4 , pp. 453-461
    • Abelson, M.B.1    Gomes, P.J.2
  • 61
    • 1642290810 scopus 로고    scopus 로고
    • Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration
    • Vogelson CT, Abelson MB, Pasquine T et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc. 25(1), 69-75 (2004).
    • (2004) Allergy Asthma Proc , vol.25 , Issue.1 , pp. 69-75
    • Vogelson, C.T.1    Abelson, M.B.2    Pasquine, T.3
  • 62
    • 34548641129 scopus 로고    scopus 로고
    • Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis
    • Abelson MB, Gomes PJ, Pasquine T, Edwards MR, Gross RD, Robertson SM. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc. 28(4), 427-433 (2007).
    • (2007) Allergy Asthma Proc , vol.28 , Issue.4 , pp. 427-433
    • Abelson, M.B.1    Gomes, P.J.2    Pasquine, T.3    Edwards, M.R.4    Gross, R.D.5    Robertson, S.M.6
  • 63
    • 39149085368 scopus 로고    scopus 로고
    • Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge
    • Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr. Eye Res. 32(12), 1017-1022 (2007).
    • (2007) Curr. Eye Res. , vol.32 , Issue.12 , pp. 1017-1022
    • Abelson, M.B.1    Spangler, D.L.2    Epstein, A.B.3    Mah, F.S.4    Crampton, H.J.5
  • 65
    • 34347262074 scopus 로고    scopus 로고
    • Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge
    • Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr. Med. Res. Opin. 23(6), 1445-1452 (2007).
    • (2007) Curr. Med. Res. Opin. , vol.23 , Issue.6 , pp. 1445-1452
    • Mah, F.S.1    Rosenwasser, L.J.2    Townsend, W.D.3    Greiner, J.V.4    Bensch, G.5
  • 66
    • 61749094990 scopus 로고    scopus 로고
    • A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis
    • Rosenwasser LJ, Mahr T, Abelson MB, Gomes PJ, Kennedy K. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proc. 29(6), 644-653 (2008).
    • (2008) Allergy Asthma Proc , vol.29 , Issue.6 , pp. 644-653
    • Rosenwasser, L.J.1    Mahr, T.2    Abelson, M.B.3    Gomes, P.J.4    Kennedy, K.5
  • 67
    • 41749103627 scopus 로고    scopus 로고
    • Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis
    • Scoper SV, Berdy GJ, Lichtenstein SJ et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv. Ther. 24(6), 1221-1232 (2007).
    • (2007) Adv. Ther. , vol.24 , Issue.6 , pp. 1221-1232
    • Scoper, S.V.1    Berdy, G.J.2    Lichtenstein, S.J.3
  • 68
    • 39749169725 scopus 로고    scopus 로고
    • Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye
    • Mah FS, O'Brien T, Kim T, Torkildsen G. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr. Med. Res. Opin. 24(2), 441-447 (2008).
    • (2008) Curr. Med. Res. Opin. , vol.24 , Issue.2 , pp. 441-447
    • Mah, F.S.1    O'Brien, T.2    Kim, T.3    Torkildsen, G.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.